<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620890</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-0575</org_study_id>
    <nct_id>NCT03620890</nct_id>
  </id_info>
  <brief_title>Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy</brief_title>
  <acronym>Determin</acronym>
  <official_title>Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy: a Comparative-effectiveness, Open Label, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether use of detemir compared to neutral protamine hagedorn (NPH) decreases
      rates of composite neonatal outcome and maternal hypoglycemia events in women with Type 2
      Diabetes Mellitus (T2DM).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite adverse neonatal outcome</measure>
    <time_frame>at the time of discharge (about 2-7 days after birth)</time_frame>
    <description>Adverse Neonatal Outcome includes any of the following:
Neonatal intensive care unit (NICU) admission or
Neonatal hypoglycemia (&lt;40 mg/dL in the first 24 hours of life and less than 50 mg/dL after) or requiring medical therapy or
Respiratory distress (need for at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure or ventilation at the first 24 hours of life or
Shoulder dystocia - defined as the need for any extra maneuvers, other than gentle downward traction of the fetal head in order to deliver the fetal body after the fetal head has been delivered or
Large for gestational age (LGA) -weight over 90th percentile of the expected value according to gestational age or
Macrosomia- Fetal weight above 4000g</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal Mean fasting glucose</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Mean post prandial glucose</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal # of subjects who experienced Hypoglycemic events (&lt;60 mg/dl)</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal weight gain during pregnancy</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of subjects who had Gestational hypertension</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of subjects who had Preeclampsia</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of subjects who had Cesarean delivery</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of subjects who had Operative vaginal delivery</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Gestational age at delivery</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of neonates who where Small for gestational age (SGA)</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit (NICU) length of stay</measure>
    <time_frame>delivery to discharge (2-7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of neonates who had 5-minute Apgar score ≤ 5</measure>
    <time_frame>5 min. after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of neonates who had jaundice requiring therapy</measure>
    <time_frame>delivery to discharge (2-7 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Neutral Protamine Hagedorn (NPH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Detemir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral Protamine Hagedorn (NPH)</intervention_name>
    <description>NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
    <arm_group_label>Neutral Protamine Hagedorn (NPH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir insulin</intervention_name>
    <description>Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
    <arm_group_label>Detemir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preexisting type 2 diabetes mellitus requiring medical treatment or

          -  overt diabetes diagnosed prior to 20 weeks of gestation using either Hemoglobin A1c
             (HBA1C) ≥ 6.5 or fasting glucose ≥126 mg/dl or random blood glucose ≥ 200 mg/dl or two
             step method ( 50g glucose challenge test (GCT) &gt;135 mg/dl followed by 100 GCT with at
             least 2 values above thresholds: Fasting Blood Glucose (FBG) &gt;90, 1 hr &gt;180, 2 hr &gt;
             155, 3 hr &gt; 140 mg/dl).

          -  Gestational age ≤20 weeks

          -  Willing to start insulin therapy or to continue insulin treatment during pregnancy

          -  Singleton or twin pregnancy

        Exclusion Criteria:

          -  Known allergy/prior adverse reaction to NPH/detemir

          -  Patients &lt;18y

          -  Known major fetal anomalies

          -  Diabetic nephropathy (Creatinine (Cr)≥1.5)

          -  Diabetic proliferative retinopathy

          -  Patients with Type 1 diabetes or gestational diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Fishel Bartal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center of Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Michal Fishel Bartal</investigator_full_name>
    <investigator_title>Assistant Professor of OB GYN</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

